GO:0090026 positive regulation of monocyte chemotaxis: Immune Recruitment Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090026 (positive regulation of monocyte chemotaxis) describes any process that increases the frequency, rate, or extent of monocyte chemotaxis, the directed migration of monocytes along chemical gradients.
• The term is a biological_process child of monocyte chemotaxis regulation and is central to inflammation, tumor immunity, and tissue repair.
• Key molecular drivers include chemokines such as CCL2, CCL28, and their receptors CCR2 and CCR10, as well as cytokines like CSF1 and IL-6 [2,3,8].
• Macrophage polarization states (M1 vs M2) shape the chemokine milieu and thereby influence monocyte recruitment.
• Dysregulated positive regulation of monocyte chemotaxis contributes to cancer progression, autoimmune diseases such as rheumatoid arthritis, and metabolic/heart failure conditions [2,4,8].
• CRISPR-based knockout, knock-in, point-mutation, and overexpression models enable causal testing of candidate regulators in monocyte migration assays.
Description
Monocytes are circulating innate immune cells that are recruited to tissues in response to injury, infection, and tumor-derived signals. The Gene Ontology term GO:0090026, positive regulation of monocyte chemotaxis, captures any process that increases the frequency, rate, or extent of monocyte chemotaxis, the directed movement of monocytes along chemical gradients. This term is essential for understanding how the immune system amplifies or sustains monocyte recruitment during inflammation and cancer [1,2]. Chemokines such as CCL2 and CCL28, acting through receptors like CCR2 and CCR10, are well-documented positive regulators of monocyte migration [2,8]. In the tumor microenvironment, cancer cell-macrophage crosstalk via the STAT3/CCL2/IL-6 axis enhances monocyte recruitment and promotes progression, illustrating the pathological importance of this process. Similarly, CSF1/CSF1R signaling inhibition reprograms tumor-associated macrophages and alters T-cell infiltration, highlighting the therapeutic relevance of modulating monocyte chemotaxis. Because monocyte recruitment is a critical step in both protective immunity and disease pathology, researchers need robust models to dissect the molecular regulators of GO:0090026. Single-cell RNA-sequencing studies have revealed distinct immune microenvironments in which monocyte chemotaxis is active, such as venous tumor thrombus in hepatocellular carcinoma and low-grade glioma [5,7]. Peripheral immune profiling in frontotemporal dementia further suggests that monocyte migration may be altered in neurodegenerative conditions. This article provides a research-grade overview of GO:0090026, its mechanisms, key genes, disease links, and experimental methods, with a focus on CRISPR-based approaches for functional validation.
positive regulation of monocyte chemotaxis At A Glance
| GO ID | GO:0090026 |
|---|---|
| GO term | positive regulation of monocyte chemotaxis |
| Ontology | biological_process |
| Synonym | none |
| Major function | Enhances the directed migration of monocytes along chemical gradients |
| Parent term | regulation of monocyte chemotaxis |
| Related process | monocyte chemotaxis (GO:0002548) |
| Key regulators | CCL2, CCL28, CCR2, CCR10, CSF1, IL-6, STAT3 |
| Disease relevance | Cancer, rheumatoid arthritis, heart failure, neurodegeneration |
What Is GO:0090026?
GO:0090026, positive regulation of monocyte chemotaxis, is defined as any process that increases the frequency, rate, or extent of monocyte chemotaxis. In other words, it encompasses all molecular and cellular events that enhance the directed migration of monocytes toward chemical cues, typically chemokines. This term is a biological_process and is distinct from the broader regulation of monocyte chemotaxis because it specifically requires a net positive effect on migration. Positive regulators can act by increasing chemokine production, enhancing chemokine receptor signaling, or modulating adhesion and cytoskeletal dynamics in monocytes.
Why Is positive regulation of monocyte chemotaxis Important in Cell Biology?
Positive regulation of monocyte chemotaxis is a central control point in innate immunity and inflammation. It determines how quickly and how many monocytes are recruited to sites of infection, injury, or tumor growth. Dysregulation of this process can lead to excessive inflammation, tissue damage, or impaired immune surveillance. Understanding the positive regulators of monocyte chemotaxis is therefore critical for developing therapies that either boost recruitment for anti-tumor immunity or dampen it in autoimmune and inflammatory diseases [1,2,3,8].
• Drives monocyte recruitment to inflamed tissues, a hallmark of acute and chronic inflammation.
• Promotes tumor-associated macrophage accumulation, supporting cancer progression and immune evasion [2,3].
• Contributes to rheumatoid arthritis pathogenesis via chemokine pathways such as CCL28-CCR10.
• Is implicated in metabolic and cardiovascular conditions, including non-alcoholic fatty liver disease and heart failure.
• May be altered in neurodegenerative diseases such as frontotemporal dementia.
• Serves as a therapeutic target for reprogramming the tumor microenvironment.
• Provides a mechanistic link between cancer cells and immune cells via STAT3/CCL2/IL-6 signaling.
• Is essential for understanding immune cell dynamics in single-cell resolved tissue contexts [5,7].
• Enables functional validation of chemokine and cytokine networks using CRISPR screens.
• Underpins the development of anti-inflammatory and immunomodulatory drugs.
What Happens During positive regulation of monocyte chemotaxis?
Chemokine Production and Gradient Formation
In simple terms: Cells release chemical signals that attract monocytes.
Positive regulation begins with the production and secretion of chemokines such as CCL2 and CCL28 by tissue-resident cells, cancer cells, or immune cells. In bladder cancer, downregulation of SPOP leads to increased CCL2 expression via the STAT3/IL-6 axis, which enhances monocyte recruitment. Similarly, in rheumatoid arthritis, the CCL28-CCR10 pathway promotes monocyte migration. These chemokines form a gradient that guides monocytes toward the source.
Receptor Activation on Monocytes
In simple terms: Monocytes detect the chemical signals through specific receptors.
Monocytes express chemokine receptors such as CCR2 and CCR10, which bind CCL2 and CCL28, respectively. Receptor activation triggers intracellular signaling cascades that lead to cytoskeletal rearrangement and directional migration [2,8]. The expression levels of these receptors can be modulated by cytokines like CSF1, which reprograms tumor-associated macrophages and influences monocyte recruitment.
Integration of Cytokine and Growth Factor Signals
In simple terms: Other immune signals can amplify or fine-tune monocyte attraction.
Cytokines such as IL-6 and growth factors like CSF1 can enhance monocyte chemotaxis by upregulating chemokine production or receptor sensitivity. For example, CSF1/CSF1R signaling inhibition with pexidartinib reprograms tumor-associated macrophages and stimulates T-cell infiltration, indirectly affecting monocyte recruitment dynamics. The STAT3 pathway is a key integrator of these signals, as shown in bladder cancer where STAT3 drives CCL2 and IL-6 expression.
Adhesion and Transendothelial Migration
In simple terms: Monocytes stick to blood vessel walls and squeeze through to reach tissues.
Once activated by chemokines, monocytes undergo adhesion to endothelial cells and transendothelial migration. This step involves integrins and adhesion molecules, and is positively regulated by chemokine signaling. In the tumor microenvironment, macrophage polarization states (M1 vs M2) influence the expression of adhesion molecules and chemokines, thereby modulating monocyte recruitment.
Amplification Loops and Feedback
In simple terms: Recruited monocytes can call in more monocytes.
Recruited monocytes can differentiate into macrophages and secrete additional chemokines, creating a positive feedback loop that amplifies monocyte chemotaxis. This is observed in cancer cell-macrophage crosstalk, where macrophages produce IL-6 and CCL2, further enhancing monocyte recruitment. Such amplification loops are critical in chronic inflammatory diseases and tumor progression.
Key Genes Involved in GO:0090026 positive regulation of monocyte chemotaxis
The following genes and proteins are established positive regulators or effectors of monocyte chemotaxis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCL2 | Chemokine that attracts monocytes via CCR2 | Key mediator of tumor-associated macrophage recruitment |
| CCL28 | Chemokine that attracts monocytes via CCR10 | Implicated in rheumatoid arthritis monocyte migration |
| CCR2 | Receptor for CCL2 on monocytes | Target for modulating monocyte recruitment in cancer |
| CCR10 | Receptor for CCL28 on monocytes | Mediates monocyte chemotaxis in arthritis |
| STAT3 | Transcription factor driving CCL2 and IL-6 expression | Central node in cancer cell-macrophage crosstalk |
| IL6 | Cytokine that enhances chemokine production | Amplifies monocyte recruitment in tumors |
| CSF1 | Growth factor that regulates macrophage polarization | Influences monocyte recruitment and T-cell infiltration |
| CSF1R | Receptor for CSF1 | Target of pexidartinib in sarcoma microenvironment |
| SPOP | E3 ubiquitin ligase that downregulates STAT3/CCL2/IL-6 | Loss promotes monocyte chemotaxis in bladder cancer |
| VEZF1 | Transcription factor regulating SPOP | Upstream regulator of the STAT3/CCL2/IL-6 axis |
| CD8A | Marker of exhausted T cells in glioma | Associated with immune microenvironment maintaining tumor growth |
| PTPRC | CD45, pan-leukocyte marker | Used to identify monocytes in single-cell studies |
| LYZ | Lysozyme, monocyte/macrophage marker | Expressed in recruited monocytes |
| CD14 | Monocyte surface marker | Used for monocyte identification in peripheral immune profiling |
| FCGR3A | CD16, marker of non-classical monocytes | Distinguishes monocyte subsets in dementia |
| CCR7 | Chemokine receptor involved in immune cell migration | May influence monocyte trafficking in inflammation |
| CX3CR1 | Fractalkine receptor on monocytes | Mediates monocyte adhesion and migration |
How Is positive regulation of monocyte chemotaxis Regulated?
Positive regulation of monocyte chemotaxis is controlled at multiple levels. Transcriptional regulation of chemokines such as CCL2 and CCL28 is driven by transcription factors including STAT3 and VEZF1. Post-translational modifications, such as ubiquitination of STAT3 by SPOP, can downregulate chemokine production and thereby reduce monocyte recruitment. Cytokine signaling through CSF1R modulates macrophage polarization and the secretion of chemokines that attract monocytes. Additionally, the balance between M1 and M2 macrophage states influences the overall chemokine milieu and the extent of monocyte chemotaxis. Feedback loops involving IL-6 and CCL2 can further amplify the response.
positive regulation of monocyte chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPOP | Bladder cancer progression via STAT3/CCL2/IL-6 | SPOP knockout bladder cancer cell lines co-cultured with monocytes |
| CCL2 | Tumor-associated macrophage recruitment | CCL2 overexpression or knockout in cancer cells followed by monocyte migration assay |
| CCL28 | Rheumatoid arthritis monocyte migration | CCL28 knockout or knockdown in synovial fibroblasts |
| CSF1 | Sarcoma tumor microenvironment | CSF1 overexpression in sarcoma cells with macrophage co-culture |
| STAT3 | Cancer cell-macrophage crosstalk | STAT3 knockout or point-mutation in cancer cells |
Cancer Progression and Tumor Microenvironment
Positive regulation of monocyte chemotaxis is a double-edged sword in cancer. In bladder cancer, SPOP downregulation leads to increased STAT3/CCL2/IL-6 signaling, which promotes monocyte recruitment and cancer progression. In sarcoma, CSF1/CSF1R inhibition reprograms tumor-associated macrophages and stimulates T-cell infiltration, suggesting that monocyte chemotaxis can be therapeutically modulated. Single-cell studies in hepatocellular carcinoma venous tumor thrombus have revealed distinct immune microenvironments with active monocyte recruitment. In low-grade glioma, a targetable CD8+ exhausted T cell population maintains tumor growth, and monocyte/macrophage dynamics are part of this ecosystem.
Autoimmune and Inflammatory Diseases
In rheumatoid arthritis, the CCL28-CCR10 pathway promotes monocyte migration into inflamed joints, contributing to synovial inflammation and joint destruction. This highlights the role of positive regulation of monocyte chemotaxis in chronic inflammatory diseases. Targeting this pathway could reduce monocyte infiltration and alleviate disease severity.
Metabolic and Cardiovascular Disorders
A comprehensive bioinformatics and Mendelian randomization analysis linked non-alcoholic fatty liver disease and heart failure to immune cell infiltration, including monocyte chemotaxis pathways. This suggests that positive regulation of monocyte chemotaxis may contribute to the pathogenesis of metabolic and cardiovascular diseases, potentially through chronic low-grade inflammation.
Neurodegeneration
Peripheral immune profiling in frontotemporal dementia revealed alterations in monocyte populations, suggesting that monocyte chemotaxis may be dysregulated in neurodegenerative conditions. Although the exact mechanisms remain to be fully elucidated, these findings point to a role for monocyte recruitment in neuroinflammation.
From positive regulation of monocyte chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SPOP increase monocyte chemotaxis? | SPOP knockout in bladder cancer cells followed by monocyte migration assay |
| Does CCL2 overexpression enhance monocyte recruitment? | CCL2 overexpression in tumor cells with transwell migration |
| Does a point mutation in CCR2 affect monocyte chemotaxis? | CCR2 point-mutation knock-in in monocytic cell lines |
| Does CSF1R inhibition alter monocyte recruitment? | CSF1R knockout or small molecule inhibition in sarcoma models |
| Does STAT3 drive CCL2 and IL-6 expression? | STAT3 knockout or knock-in of constitutively active STAT3 |
| Can we identify novel regulators of monocyte chemotaxis? | Genome-wide CRISPR knockout library screening in cancer cells co-cultured with monocytes |
How to Study the positive regulation of monocyte chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell migration assay | Number of migrated monocytes | Testing chemokine or receptor function [2,8] |
| Single-cell RNA-seq | Gene expression in individual cells | Identifying monocyte subsets and chemokine profiles [5,7] |
| Flow cytometry | Surface marker expression | Quantifying monocyte populations and receptor levels |
| Bioinformatics / Mendelian randomization | Genetic causal inference | Linking monocyte chemotaxis genes to disease |
| CRISPR knockout screening | Loss-of-function effects on migration | Identifying novel regulators of monocyte chemotaxis |
| Western blot | Protein expression and phosphorylation | Validating STAT3 or SPOP modulation |
| ELISA | Cytokine/chemokine secretion | Measuring CCL2, IL-6, or CCL28 levels [2,8] |
| Immunohistochemistry | Tissue localization of monocytes | Assessing monocyte infiltration in tumors |
Transwell Migration Assays
Transwell assays are the gold standard for measuring monocyte chemotaxis in vitro. Monocytes are placed in the upper chamber and chemoattractants in the lower chamber; migrated cells are counted. This method can be used to test the effect of genetic perturbations (e.g., knockout of CCL2 or CCR2) on monocyte migration [2,8].
Single-Cell RNA Sequencing
Single-cell RNA sequencing allows unbiased profiling of monocyte and macrophage populations in tissues, revealing chemokine expression and receptor profiles. This has been applied to hepatocellular carcinoma venous tumor thrombus and glioma to identify immune cell subsets involved in monocyte chemotaxis [5,7].
Flow Cytometry and Immune Profiling
Flow cytometry can quantify monocyte subsets and their expression of chemokine receptors. Peripheral immune profiling in frontotemporal dementia used flow cytometry to identify monocyte alterations. This method is useful for validating CRISPR-mediated changes in receptor expression.
Bioinformatics and Mendelian Randomization
Bioinformatics analyses of transcriptomic datasets and Mendelian randomization can identify causal links between monocyte chemotaxis genes and diseases. For example, a study on non-alcoholic fatty liver disease and heart failure used these methods to implicate immune cell infiltration.
How CRISPR Can Be Used to Study GO:0090026 positive regulation of monocyte chemotaxis
Knockout
CRISPR knockout is used to delete genes such as CCL2, CCR2, STAT3, or SPOP to determine their requirement for monocyte chemotaxis. For example, SPOP knockout in bladder cancer cells increases CCL2 and IL-6 expression, enhancing monocyte recruitment. Knockout of CCR2 in monocytes abolishes CCL2-directed migration.
Point Mutation
Point mutations can be introduced to model specific amino acid changes that affect chemokine or receptor function. For instance, mutating key residues in CCR2 can disrupt ligand binding and impair monocyte chemotaxis. This approach helps dissect signaling domains and disease-associated variants.
Knock-in
Knock-in of tagged or reporter genes allows tracking of chemokine expression or monocyte migration in real time. For example, knocking in a fluorescent reporter under the CCL2 promoter enables visualization of chemokine production in live tissues. Knock-in of human CCL2 into mouse models can humanize the chemokine axis for drug testing.
Overexpression
Overexpression of chemokines such as CCL2 or CCL28 in cancer cells or fibroblasts enhances monocyte chemotaxis in co-culture assays [2,8]. Overexpression of constitutively active STAT3 mimics the effects of SPOP loss and increases monocyte recruitment. This approach is useful for gain-of-function studies.
How EDITGENE Supports positive regulation of monocyte chemotaxis Research
Researchers studying positive regulation of monocyte chemotaxis-related genes often need to determine whether a candidate gene is causally involved in monocyte recruitment or is merely a bystander. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal testing, from knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of monocyte chemotaxis research.
Frequently Asked Questions About positive regulation of monocyte chemotaxis
What is GO:0090026 positive regulation of monocyte chemotaxis?
GO:0090026 is a Gene Ontology biological process term defined as any process that increases the frequency, rate, or extent of monocyte chemotaxis, the directed migration of monocytes along chemical gradients.
What genes are involved in positive regulation of monocyte chemotaxis?
Key genes include CCL2, CCL28, CCR2, CCR10, STAT3, IL6, CSF1, CSF1R, and SPOP, as shown in studies of cancer and rheumatoid arthritis [2,3,8].
How is monocyte chemotaxis positively regulated in cancer?
In cancer, tumor cells and macrophages secrete chemokines like CCL2 and IL-6, often via STAT3 signaling, which recruit monocytes to the tumor microenvironment and promote progression.
What diseases are associated with dysregulated monocyte chemotaxis?
Dysregulated monocyte chemotaxis is linked to cancer, rheumatoid arthritis, non-alcoholic fatty liver disease, heart failure, and frontotemporal dementia [2,4,6,8].
What methods are used to study positive regulation of monocyte chemotaxis?
Common methods include transwell migration assays, single-cell RNA sequencing, flow cytometry, ELISA, and CRISPR-based genetic screens [2,5,6,8].
How can CRISPR be used to study monocyte chemotaxis?
CRISPR knockout, knock-in, point mutation, and overexpression models allow researchers to test the causal role of specific genes in monocyte recruitment, such as knocking out CCR2 or overexpressing CCL2 [2,8].
What is the role of CCL2 in monocyte chemotaxis?
CCL2 is a chemokine that binds CCR2 on monocytes, inducing directed migration. It is a major positive regulator of monocyte chemotaxis in inflammation and cancer.
What is the CCL28-CCR10 pathway?
The CCL28-CCR10 pathway is a chemokine-receptor axis that promotes monocyte migration, particularly in rheumatoid arthritis.
How does SPOP regulate monocyte chemotaxis?
SPOP is an E3 ubiquitin ligase that downregulates STAT3, CCL2, and IL-6. Loss of SPOP increases these factors and enhances monocyte chemotaxis in bladder cancer.
Can monocyte chemotaxis be therapeutically targeted?
Yes, inhibiting chemokine receptors or signaling pathways, such as CSF1R with pexidartinib, can reprogram the tumor microenvironment and alter monocyte recruitment.
Conclusion
GO:0090026 positive regulation of monocyte chemotaxis is a fundamental biological process that governs the recruitment of monocytes to tissues in health and disease. Its dysregulation contributes to cancer progression, autoimmune diseases, and metabolic disorders. Understanding the molecular players, such as CCL2, CCL28, STAT3, and SPOP, provides opportunities for therapeutic intervention. CRISPR-based models are powerful tools for dissecting these pathways and validating candidate targets. EDITGENE offers comprehensive services to support such research, from knockout to overexpression and library screening.
References
- 1. Orecchioni M et al.. 2019. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.. Front Immunol 10:1084 PMID: 31178859
- 2. Li M et al.. 2024. SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1.. Theranostics 14(17):6543-6559 PMID: 39479456
- 3. Fujiwara T et al.. 2021. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.. Mol Cancer Ther 20(8):1388-1399 PMID: 34088832
- 4. Zhang Y et al.. 2024. Non-alcoholic fatty liver disease and heart failure: A comprehensive bioinformatics and Mendelian randomization analysis.. ESC Heart Fail 11(6):4185-4200 PMID: 39143741
- 5. Zhou KQ et al.. 2025. Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.. Hepatology 82(3):566-581 PMID: 40833994
- 6. Gamez N et al.. 2026. Peripheral immune profiling in frontotemporal dementia.. Brain Commun 8(2):fcag089 PMID: 41924698
- 7. Barakat R et al.. 2024. Human single cell RNA-sequencing reveals a targetable CD8(+) exhausted T cell population that maintains mouse low-grade glioma growth.. Nat Commun 15(1):10312 PMID: 39609412
- 8. Cheng F et al.. 2022. [Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis].. Beijing Da Xue Xue Bao Yi Xue Ban 54(6):1074-1078 PMID: 36533335
